breast cancer - HR positive | |
la/mBC - HR positive - L2 - PIK3CA mutant | |
phosphoinositide 3-kinase (PI3K) inhibitor | |
buparlisib based treatment | |
buparlisib plus fulvestrant | BELLE-2 ... |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-